WS Investor
13 Feb 2026, 19:48
DexCom reported strong fourth quarter and full-year 2025 results, driven by double-digit revenue growth and margin expansion.
In Q4 2025, revenue rose 13% year over year to $1.26 billion (12% organic). U.S. revenue increased 11%, while international revenue grew 18%. GAAP operating income reached $323.0 million (25.6% margin), up 860 basis points from the prior year. GAAP net income was $267.3 million, or $0.68 per diluted share.
For full-year 2025, revenue grew 16% to $4.66 billion (15% organic). GAAP operating income totaled $911.8 million (19.6% margin), and non-GAAP operating income reached $969.3 million (20.8% margin).
Strategically, Dexcom launched the G7 15 Day CGM system in the U.S., received FDA clearance for Smart Basal, and expanded CGM coverage in Québec.
For 2026, Dexcom reaffirmed guidance of $5.16–$5.25 billion in revenue (11–13% growth), non-GAAP operating margin of 22–23%, and adjusted EBITDA margin of 30–31%. The company ended the year with $2.0 billion in cash and no borrowings under its credit facility.
Business Wire
In Q4 2025, revenue rose 13% year over year to $1.26 billion (12% organic). U.S. revenue increased 11%, while international revenue grew 18%. GAAP operating income reached $323.0 million (25.6% margin), up 860 basis points from the prior year. GAAP net income was $267.3 million, or $0.68 per diluted share.
For full-year 2025, revenue grew 16% to $4.66 billion (15% organic). GAAP operating income totaled $911.8 million (19.6% margin), and non-GAAP operating income reached $969.3 million (20.8% margin).
Strategically, Dexcom launched the G7 15 Day CGM system in the U.S., received FDA clearance for Smart Basal, and expanded CGM coverage in Québec.
For 2026, Dexcom reaffirmed guidance of $5.16–$5.25 billion in revenue (11–13% growth), non-GAAP operating margin of 22–23%, and adjusted EBITDA margin of 30–31%. The company ended the year with $2.0 billion in cash and no borrowings under its credit facility.
Business Wire
